← Back to Search

Virtual Group Speech Therapy for Head and Neck Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 6 weeks post radiation

Awards & highlights

Study Summary

This trial will study how a virtual, group-based therapy, with a patient partner, can improve care for head and neck cancer patients.

Who is the study for?

Adults over 18 with head or neck cancer starting chemoradiotherapy for cure can join. They need a radiation dose of at least 60 Grays and must speak French well enough for questionnaires. Those with distant cancer spread, planned total laryngectomy, prior severe swallowing issues, another simultaneous cancer, previous head/neck radiation, or significant cognitive impairments cannot participate.Check my eligibility

What is being tested?

The trial is testing the eG2 Intervention: a virtual group speech therapy guided by a patient partner to prevent swallowing difficulties in patients undergoing chemoradiotherapy for head and neck cancers. It aims to improve care quality and accessibility while optimizing healthcare resources.See study design

What are the potential side effects?

Since this intervention involves speech therapy rather than medication, typical drug side effects are not expected. However, participants may experience fatigue from regular sessions or stress from technology use.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 6 weeks post radiation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 6 weeks post radiation

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 6 weeks post radiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of nasogastric tube

Trial Design

1Treatment groups

Experimental Treatment

Group I: virtual group speech therapy intervention guided by a patient partnerExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor

366 Previous Clinical Trials

129,561 Total Patients Enrolled

Université du Québec à Trois-RivièresOTHER

42 Previous Clinical Trials

4,307 Total Patients Enrolled

Media Library

Virtual Group Speech Pathology Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05621889 — Phase 1 & 2

Swallowing Difficulty Research Study Groups: virtual group speech therapy intervention guided by a patient partner

Swallowing Difficulty Clinical Trial 2023: Virtual Group Speech Pathology Intervention Highlights & Side Effects. Trial Name: NCT05621889 — Phase 1 & 2

Virtual Group Speech Pathology Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05621889 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still active in this examination?

"According to clinicaltrials.gov, this medical study is not currently looking for participants; it was initially listed on June 2nd 2023 and the most recent edit was done on June 1st 2023. However, there are numerous other trials that have opened up recruitment at the moment with 447 presently enrolling patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Innovative Patient-partner-guided Virtual Group Speech Pathology Intervention Model in Head and Neck Cancer

Houda Bahig 2023. "Innovative Patient-partner-guided Virtual Group Speech Pathology Intervention Model in Head and Neck Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05621889.

All > Pathology